Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
2014년 9월 3일 업데이트: Takeda
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
연구 개요
상세 설명
Gout is caused by high levels of uric acid in the body, and is associated with a broad range of comorbidities including heart disease, chronic kidney disease and additional risk factors like obesity and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form from supersaturated body fluids and settle in joints and other organs. Urate-lowering therapy is used to treat hyperuricemia in patients with gout.
Current treatments focus on initiating urate-lowering therapy in hyperuricemic gout patients who have experienced multiple acute gout flares within the past year. However, joint damage caused by crystal deposition may occur much earlier than previously considered. Monosodium urate crystals have been found present in the joints of people with hyperuricemia who do not have any symptoms. The presence of monosodium urate crystals would indicate that after the crystals form, they stay within the joint if serum urate levels are not reduced. Lowering uric acid levels and maintaining them may reduce acute gout flare episodes and possibly halt or reduce joint damage in patients with gout.
This study will evaluate the effect of febuxostat on joint damage in hyperuricemic patients with early gout. All patients will receive gout flare prophylaxis for the first 6 months of the study. Gout flares may also be treated throughout the study.
A variety of imaging techniques are in use to evaluate gout. Plain radiographs (x-rays), Magnetic Resonance Imaging (MRI) and Dual Energy Computed Tomography (DECT) will be utilized in this study. The modified Sharp/Van Der Heijde scoring method (named after Drs. Sharp and Van Der Heijde) for assessment of x-rays has been validated in patients with chronic gout and will be used in this study for evaluating erosion and joint space narrowing. Participants are expected to have 15 visits which will include plain radiographic examinations at 5 visits, 3 Magnetic Resonance Imaging (MRI) examinations and 3 DECT procedures at selected sites.
연구 유형
중재적
등록 (실제)
314
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Arizona
-
Mesa, Arizona, 미국
-
Tucson, Arizona, 미국
-
-
California
-
Burbank, California, 미국
-
Carmichael, California, 미국
-
Costa Mesa, California, 미국
-
Irvine, California, 미국
-
Orange, California, 미국
-
Rancho Cucamonga, California, 미국
-
San Diego, California, 미국
-
San Luis Obispo, California, 미국
-
-
Connecticut
-
Trumbull, Connecticut, 미국
-
-
Florida
-
Boynton Beach, Florida, 미국
-
Daytona Beach, Florida, 미국
-
Fort Lauderdale, Florida, 미국
-
Hialeah, Florida, 미국
-
Miami, Florida, 미국
-
Sanford, Florida, 미국
-
Tampa, Florida, 미국
-
Winter Park, Florida, 미국
-
-
Hawaii
-
Honolulu, Hawaii, 미국
-
-
Illinois
-
Arlington Heights, Illinois, 미국
-
-
Indiana
-
Avon, Indiana, 미국
-
Greenfield, Indiana, 미국
-
-
Kansas
-
Wichita, Kansas, 미국
-
-
Maine
-
Rockport, Maine, 미국
-
-
Minnesota
-
Chaska, Minnesota, 미국
-
-
Mississippi
-
Belzoni, Mississippi, 미국
-
Olive Branch, Mississippi, 미국
-
-
Montana
-
Billings, Montana, 미국
-
Missoula, Montana, 미국
-
-
Nebraska
-
Bellevue, Nebraska, 미국
-
-
Nevada
-
Henderson, Nevada, 미국
-
Las Vegas, Nevada, 미국
-
-
New Mexico
-
Albuquerque, New Mexico, 미국
-
-
North Carolina
-
Charlotte, North Carolina, 미국
-
Lenoir, North Carolina, 미국
-
Shelby, North Carolina, 미국
-
-
Ohio
-
Dayton, Ohio, 미국
-
Franklin, Ohio, 미국
-
Willoughby Hills, Ohio, 미국
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국
-
-
Oregon
-
Eugene, Oregon, 미국
-
-
Pennsylvania
-
Duncansville, Pennsylvania, 미국
-
-
Rhode Island
-
East Providence, Rhode Island, 미국
-
-
South Carolina
-
Columbia, South Carolina, 미국
-
-
South Dakota
-
Rapid City, South Dakota, 미국
-
-
Tennessee
-
Kingsport, Tennessee, 미국
-
-
Texas
-
Austin, Texas, 미국
-
Houston, Texas, 미국
-
San Antonio, Texas, 미국
-
Southlake, Texas, 미국
-
Sugar Land, Texas, 미국
-
-
Virginia
-
Arlington, Virginia, 미국
-
Burke, Virginia, 미국
-
Manassas, Virginia, 미국
-
-
Wisconsin
-
Kenosha, Wisconsin, 미국
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- The participant, or the participant's legally acceptable representative, signs a written informed consent form/Health Insurance Portability & Accountability Act (HIPAA) Authorization prior to the initiation of any study procedures.
Must have a history or presence of gout defined as having one or more of the following conditions of the American Rheumatism Association (ARA) preliminary criteria for the diagnosis of gout
- A tophus proven to contain urate crystals by chemical or polarized light microscopic means and/or
- Characteristic urate crystals in the joint fluid and/or
History of at least 6 of the following clinical, laboratory and x-ray phenomena*: *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
- More than one attack of acute arthritis*
- maximum inflammation developed within 1 day
- monoarticular arthritis
- redness observed over joints
- first metatarsophalangeal joint painful or swollen
- unilateral first metatarsophalangeal joint attack
- unilateral tarsal joint attack
- tophus (proven or suspected)
- hyperuricemia
- asymmetric swelling within a joint on x-ray
- sub-cortical cysts without erosions on x-ray
- joint fluid culture negative for organisms during attacks
- *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
Is male and at least 18 years of age OR;
- Female ≥45 years of age and at least 2 years post-menopausal AND has a Follicle Stimulating Hormone (FSH) level ≥40 IU/L OR
- Female receiving hormone replacement therapy (HRT) must be ≥55 years of age (FSH level not required).
- Has hyperuricemia defined as serum Uric Acid (sUA) level ≥7.0 mg/dL at Screening.
- Has a history of ≤2 (1 or 2) flares. In participants with a history of 2 flares, must have had only one flare in any 12 month period. The primary affected joint will be based on the location of the first gout flare which must be located within right or left metatarsophalangeal (MTP), interphalangeal (IP), ankle, metacarpophalangeal (MCP), Proximal Inter-Phalangeal (PIP), or distal inter-phalangeal (DIP) joints prior to Screening.
- Is capable of understanding and complying with protocol requirements, including scheduled clinic procedures.
Exclusion Criteria:
- Previously on urate-lowering therapy (allopurinol, febuxostat or probenecid).
- Has secondary hyperuricemia (eg due to myeloproliferative disorder or organ transplant).
- Has a history of xanthinuria.
- Has a known hypersensitivity to any component of the febuxostat formulation.
- Has rheumatoid arthritis.
- Has active peptic ulcer disease.
- Has a history of cancer, except basal cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study medication.
- Has experienced either a myocardial infarction (MI) or stroke within 90 days prior to the Screening visit.
- Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 the upper limit of normal during the Screening period.
- Has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol at the discretion of the Investigator.
- Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse with 5 years prior to the Screening visit. Participant consumes >14 alcoholic beverages/week.
- Has received any investigational medicinal product within 30 days prior to the Screening visit. In addition, the participant has been previously randomized into this study and received at least one dose of double blind study drug treatment.
- Has an estimated Glomerular filtration rate (eGFR) <60 mL/min calculated using the Modification of Diet in Renal Disease (MDRD) formula by the Central Laboratory.
- Has a serum creatinine at Screening greater than 2.0 mg/dL.
- Has a known history of infection with hepatitis B, hepatitis C or human immunodeficiency virus.
- Is a study site employee, or is an immediate family member (ie, spouse, parent, child, and sibling) of a study site employee involved in conduct of this study.
- Is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent form is available.
- Is required to take excluded medications.
Magnetic Resolution Imaging:
- Has a known hypersensitivity to gadolinium
- Has history of severe asthma
- Has an electronically, magnetically or mechanically activated implanted device
- Has any object that could present a potential hazard or interfere with MRI interpretation secondary to the artifact (i.e. metallic foreign bodies)
- Has a significant medical condition considered by the Investigator (or radiologist) to interfere with the participant's ability to receive gadolinium (eg Sickle cell anemia).
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Febuxostat 40 mg or 80 mg
Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
|
페북소스타트 캡슐
다른 이름들:
|
|
위약 비교기: Placebo
Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
|
Febuxostat placebo-matching capsules
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint
기간: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst).
Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs
기간: Baseline and Month 24
|
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320.
Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208.
The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs
기간: Baseline and Month 24
|
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
|
Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint
기간: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS).
Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20.
Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst).
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint
기간: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst).
The Erosion Score and the JSN Score were summed for the Total Score.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
유용한 링크
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2010년 3월 1일
기본 완료 (실제)
2013년 9월 1일
연구 완료 (실제)
2013년 9월 1일
연구 등록 날짜
최초 제출
2010년 2월 26일
QC 기준을 충족하는 최초 제출
2010년 3월 1일
처음 게시됨 (추정)
2010년 3월 2일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 9월 10일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 9월 3일
마지막으로 확인됨
2014년 9월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .